Financial Information

Balance Sheet

v3.8.0.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Current Assets    
Cash $ 229,828 $ 141,379
Trade accounts receivable, net 85,799 128,190
Other receivables 200,000
Product deposit 36,992 16,500
Inventory, net 601,174 681,258
Other current assets 51,735
Assets held for sale 296,483
Total Current Assets 1,205,528 1,263,810
Current Liabilities    
Accounts payable and accrued expenses 318,402 422,347
Notes payable 167,479
Liabilities held for sale 51,145
Total Current Liabilities 318,402 640,971
Stockholders' Equity (Deficit)    
Common stock, $0.01 par value; 100,000,000 shares authorized, 43,993,063 and 44,493,063 shares issued, 43,477,863 and 43,977,863 outstanding as of March 31, 2018 and December 31, 2017, respectively 429,930 444,930
Additional paid-in capital 11,139,850 11,500,537
Accumulated (deficit) (10,272,566) (10,899,843)
Equity 1,297,214 1,045,624
Treasury stock, 515,200 and 515,200 shares, at cost (163,701) (163,701)
Total Immudyne, Inc. Stockholders' (Deficit) 1,133,513 881,923
Non-controlling interest (246,387) (259,084)
Total Stockholders' (Deficit) 887,126 622,839
Total Liabilities and Stockholders' (Deficit) $ 1,205,528 $ 1,263,810

Source